| Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery EC Lee, Q Liang, H Ali, L Bayliss, A Beasley, T Bloomfield-Gerdes, ... Nature biotechnology 32 (4), 356-363, 2014 | 249 | 2014 |
| Antibodies and immunocytokines J Campbell, N Sandy, SD Gillies, V Germaschewski, C Van Krinks, I Kirby, ... US Patent 9,617,338, 2017 | 55 | 2017 |
| Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab M Kosmač, T Avčin, N Toplak, G Simonini, R Cimaz, VČ Šerbec Pediatric research 69 (3), 243-248, 2011 | 55 | 2011 |
| Antibodies and immunocytokines J Campbell, N Sandy, SD Gillies, V Germaschewski, C Van Krinks, I Kirby, ... US Patent 9,567,399, 2017 | 46 | 2017 |
| An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression RCA Sainson, AK Thotakura, M Kosmac, G Borhis, N Parveen, R Kimber, ... Cancer Immunology Research 8 (12), 1568-1582, 2020 | 36 | 2020 |
| Anti-human OX40L antibodies and methods of treatment J Campbell, S Holmes, I Kirby, M Kosmac US Patent 9,139,653, 2015 | 32 | 2015 |
| Epitope mapping of a PrP (Sc)-specific monoclonal antibody: identification of a novel C-terminally truncated prion fragment M Kosmač, S Koren, G Giachin, T Stoilova, R Gennaro, G Legname, ... Molecular immunology 48 (5), 746-750, 2011 | 30 | 2011 |
| Multispecific antibodies for immuno-oncology J Campbell, N Sandy, C Van Krinks, SJ Arkinstall, V Germaschewski, ... US Patent App. 16/311,421, 2023 | 23 | 2023 |
| Anti-human OX40L antibodies J Campbell, S Holmes, I Kirby, M Kosmac US Patent 9,234,043, 2016 | 17 | 2016 |
| Antibody variable-region sequencing as a method for hybridoma cell-line authentication S Koren, M Kosmač, A Colja Venturini, S Montanič, V Čurin Šerbec Applied microbiology and biotechnology 78, 1071-1078, 2008 | 17 | 2008 |
| Anti-ICOS antibodies RCA Sainson, SJ Arkinstall, JI Campbell, MH Ali, EC Lee, MJ McCourt, ... US Patent 9,957,323, 2018 | 13 | 2018 |
| Synergistic combinations of OX40L antibodies for the treatment of GVHD P Bland-Ward, M Kosmac, S Holmes, I Kirby, J Campbell US Patent 9,512,229, 2016 | 13 | 2016 |
| Anti-hOX40L antibodies, uses, and methods J Campbell, S Holmes, I Kirby, M Kosma US Patent 9,587,030, 2017 | 11 | 2017 |
| Anti-human OX40L antibodies and methods of treating graft versus host disease with the same P Bland-Ward, J Campbell, S Holmes, I Kirby, M Kosmac, LS Kean, ... US Patent 9,434,785, 2016 | 11 | 2016 |
| Abstract LB-153: KY1055, a novel ICOS-PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo RC Sainson, N Parveen, G Borhis, M Kosmac, T OKell, E Taggart, ... Cancer Research 78 (13_Supplement), LB-153-LB-153, 2018 | 8 | 2018 |
| Synergistic combinations of OX40L antibodies for the treatment of GvHD P Bland-Ward, M Kosmac, S Holmes, I Kirby, J Campbell US Patent 9,868,790, 2018 | 8 | 2018 |
| Characterisation of the immune repertoire of a humanised transgenic mouse through immunophenotyping and high-throughput sequencing E Richardson, Š Binter, M Kosmac, M Ghraichy, V von Niederhäusern, ... Elife 12, e81629, 2023 | 7 | 2023 |
| TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo J de Abreu CARVALHO, RJ Kimber, JI Campbell, N Sandy, C Van Krinks, ... US Patent 11,440,960, 2022 | 7 | 2022 |
| Anti-OX40L antibodies and methods of treating graft versus host disease J Campbell, S Holmes, I Kirby, M Kosma US Patent 10,669,342, 2020 | 7 | 2020 |
| Methods of treating SLE with anti-OX40L antibodies J Campbell, S Holmes, I Kirby, M Kosma US Patent 10,654,935, 2020 | 5 | 2020 |
